Canadian Paediatric Glioma therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
The paediatric brain tumor is an uncontrolled or abnormal growth of normal cells in the brain in children. Brain tumors are mainly of two types, cancerous (malignant) and noncancerous (benign). Tumors of the central nervous system (CNS) are the most frequent solid tumors in Canadian children, with approximately 5.4-5.6 diagnoses per 100,000. Of those diagnosed, 0.7 per 100,000 will succumb to their disease, making CNS tumors the leading cause of cancer-related death in children. Within this group, paediatric-type low-grade gliomas (PLGG) are the most frequent, accounting for approximately 30% of all childhood brain tumors. In Canada, 72% of children diagnosed with brain or spinal cord tumours are expected to live at least 5 years after their diagnosis. However, technological advancements in the diagnosis of gliomas and analysis of its progression through various imaging modalities have improved survival rates, thereby giving an enhanced edge for rapid evaluation of the efficacy of several pipeline drugs.
Market Driving Factors:
The driving factors in the growth of the peadiatric glioma therapeutics market include incurable status of the disease and increasing prevalence of brain disorders. A person’s risk of developing paediatric glioma depends on many factors, including genetics and exposure to risk factors.. Furthermore, the late advent of disease symptoms leads to postponement in diagnosis and progression in the cancer stage, which results in the rising cost of the treatment.